Understanding metabolism related differences in ocular efficacy of MGV354

References

• Argikar UA, Dumouchel JL, Dunne CE, Bushee AJ. (2017). Ocular non-P450 oxidative, reductive, hydrolytic, and conjugative drug metabolizing enzymes. Drug Metab Rev 49:372–94.
   PubMed Web of Science ®Google Scholar
• Argikar UA, Dumouchel JL, Dunne CE, et al. (2016). Ocular metabolism of levobunolol: historic and emerging metabolic pathways. Drug Metab Dispos 44:1304–12.
   PubMed Web of Science ®Google Scholar
• Argikar UA, Dumouchel JL, Kramlinger VM, et al. (2017). Do we need to study metabolism and distribution in the eye: why, when, and are we there yet? J Pharm Sci 106:2276–81.
   PubMed Web of Science ®Google Scholar
• Argikar UA, Gomez J, Ung D, et al. (2010). Identification of novel metoclopramide metabolites in humans: in vitro and in vivo studies. Drug Metab Dispos 38:1295–307.
   PubMed Web of Science ®Google Scholar
• Bushee JL, Argikar UA. (2011). An experimental approach to enhance precursor ion fragmentation for metabolite identification studies: application of dual collision cells in an orbital trap. Rapid Commun Mass Spectrom 25:1356–62.
   PubMed Web of Science ®Google Scholar
• Bushee JL, Dunne CE, Argikar UA. (2015). An in vitro approach to investigate ocular metabolism of a topical, selective β1-adrenergic blocking agent, betaxolol . Xenobiotica 45:396–405.
   PubMed Web of Science ®Google Scholar
• Cirello AL, Dumouchel JL, Gunduz M, et al. (2017). In vitro ocular metabolism and bioactivation of ketoconazole in rat, rabbit and human. Drug Metab Pharmacokinet 32:121–6.
   PubMed Web of Science ®Google Scholar
• Dumouchel JL, Chemuturi N, Milton MN, et al. (2018). Models and approaches describing the metabolism, transport, and toxicity of drugs administered by the ocular route. Drug Metab Dispos 46:1670–83.
   PubMed Web of Science ®Google Scholar
• Dunne CE, Bushee JL, Argikar UA. (2013). Metabolism of bromopride in mouse, rat, rabbit, dog, monkey, and human hepatocytes. Drug Metab Pharmacokinet 28:453–61.
   PubMed Web of Science ®Google Scholar
• Ehara T, Adams CM, Bevan D, et al. (2018). The discovery of ( S)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1 H-inden-4-yl)pyridin-2-yl)-5-methyl-1 H-pyrazole-4-carboxylic acid, a soluble guanylate cyclase activator specifically designed for topical ocular delivery as a therapy for glaucoma. J Med Chem 61:2552–70.
   PubMed Web of Science ®Google Scholar
• Follmann M, Griebenow N, Hahn MG, Hartung I, et al. (2013). The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew Chem Int Ed Engl 52:9442–62.
   PubMed Web of Science ®Google Scholar
• Gunduz M, Argikar UA, Baeschlin D, et al. (2010). Identification of a novel N-carbamoyl glucuronide: in vitro, in vivo, and mechanistic studies. Drug Metab Dispos 38:361–7.
   PubMed Web of Science ®Google Scholar
• Gunduz M, Argikar UA, Cirello AL, Dumouchel JL. (2018). New perspectives on acyl glucuronide risk assessment in drug discovery: investigation of in vitro stability, in situ reactivity, and bioactivation. Drug Metab Lett 12:84–92.
   PubMedGoogle Scholar
• Hagan S, Martin E, Enriquez-de-Salamanca A. (2016). Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine. EPMA J 7:15
   PubMed Web of Science ®Google Scholar
• Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–13.
   PubMed Web of Science ®Google Scholar
• Hatsis P, Waters NJ, Argikar UA. (2017). Implications for metabolite quantification by mass spectrometry in the absence of authentic standards. Drug Metab Dispos 45:492–6.
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. (2002). Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol-Chic 120:1268–79.
   PubMed Web of Science ®Google Scholar
• Holz FG, Sadda SR, Busbee B, et al. (2018). Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol 136:666–77.
   PubMed Web of Science ®Google Scholar
• Kassa E, Ciulla TA, Hussain RM, Dugel PU. (2019). Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opin Biol Ther 19:335–42.
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hussein M, et al. (2003). Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol-Chic 121:48–56.
   PubMed Web of Science ®Google Scholar
• Lin CW, Sherman B, Moore LA, et al. (2018). Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma. J Ocul Pharmacol Ther 34:40–51.
   PubMed Web of Science ®Google Scholar
• Mainolfi N, Powers J, Amin J, et al. (2013). An effective prodrug strategy to selectively enhance ocular exposure of a cannabinoid receptor (CB1/2) agonist. J Med Chem 56:5464–72.
   Google Scholar
• Nakano M, Lockhart CM, Kelly EJ, Rettie AE. (2014). Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition. Drug Metab Rev 46:247–60.
   PubMed Web of Science ®Google Scholar
• Prasanna G, Carreiro S, Anderson S, et al. (2011). Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma. Exp Eye Res 93:256–64..
   Google Scholar
• Prasanna G, Ferrara L, Adams C, et al. (2018). A novel selective soluble guanylate cyclase activator, MGV354, lowers intraocular pressure in preclinical models, following topical ocular dosing. Invest Ophthalmol Vis Sci 59:1704–16.
   PubMed Web of Science ®Google Scholar
• Quigley HA, Broman AT. (2006). The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90:262–7.
   PubMed Web of Science ®Google Scholar
• Stacy R, Huttner K, Watts J, et al. (2018). A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma. Am J Ophthalmol 192:113–23.
   PubMed Web of Science ®Google Scholar
• Tamhane M, Cabrera-Ghayouri S, Abelian G, Viswanath V. (2019). Review of biomarkers in ocular matrices: challenges and opportunities. Pharm Res 36:40.
   PubMed Web of Science ®Google Scholar
• Yin Y, Cameron MD, Lin L, et al. (2010). Discovery of potent and selective urea-based ROCK inhibitors and their effects on intraocular pressure in rats. ACS Med Chem Lett 1:175–9.
   Google Scholar